Pinealon: the Khavinson EDR tripeptide and the evidence behind it.

Pinealon is a three-amino-acid peptide (Glu-Asp-Arg, or EDR) from the Khavinson lab in Saint Petersburg. It has been marketed as a neuroprotective "peptide bioregulator" for memory and cognitive aging research. The biology is interesting. We reviewed 3 PubMed-indexed papers from 2020–2026 and found the human evidence base to be the thinnest we have encountered for any peptide in this library.

What is Pinealon?

Pinealon is a synthetic peptide made of 3 amino acids: glutamic acid, aspartic acid, and arginine. Chemists abbreviate the sequence as EDR using single-letter codes. Molecular weight is roughly 418 g/mol.

Three residues is about as short as a peptide can get and still be called a peptide. There are no chemical modifications and no linkers. That simpler chemistry makes it relatively inexpensive to synthesize — research-grade reference compound pricing has been reported at under $80 per 10 mg vial.

The molecule came out of Vladimir Khavinson's lab at the Saint Petersburg Institute of Bioregulation and Gerontology, founded in 1992. The lab's research thread on short peptides as "gene-expression regulators" goes back to the 1970s.

Pinealon sits in a family of Khavinson peptides that includes Epitalon, Vilon, Cortagen, and Livagen. All short. All synthetic. All from the same group. Pinealon's pitch is neuroprotection: cognitive support and modulation of Alzheimer's-relevant pathways.

How is it supposed to work?

The most thorough modern statement of Pinealon's proposed mechanism is the Khavinson group's 2020 review in Molecules (Khavinson et al., 2020). Two claims sit at the center of it.

1. EDR binds DNA-packaging proteins directly

The central claim: EDR sticks to histones or RNA inside the cell nucleus and changes which genes get expressed. No cell-surface receptor. No nuclear receptor. It's the same model the group proposes for Epitalon.

That's the piece outside scientists are most skeptical of. It's hard to picture how a 3-amino-acid peptide could specifically engage chromatin and produce predictable, sequence-specific transcription changes. No outside lab has shown it does.

2. Downstream signaling effects

The Khavinson team reports that EDR boosts antioxidant enzymes (SOD2 and GPX1) in cerebellar neurons, lowers two pro-death signals called caspase-3 and p53, and adjusts the MAPK/ERK signaling cascade that controls cell survival. They also report changes in serotonin levels and dendritic-spine preservation in mouse models of Alzheimer's and Huntington's.

Each individual effect is plausible. The question no one has answered: does a tripeptide with no obvious DNA-binding motif specifically produce all of these effects? Or are we looking at non-specific cellular stress responses that wouldn't reproduce in an independently designed study?

Khavinson-school peptides

Tripeptide EDR / Glu-Asp-Arg Khavinson lineage

Pinealon is on our research-content roadmap; we don’t currently stock it. The closest stocked peptide from the same Khavinson Saint Petersburg research program is Epitalon (AEDG tetrapeptide) — same lineage, same short-peptide-bioregulator concept, with a broader Western mechanistic evidence base.

Browse the catalog

What does the research actually show?

We searched PubMed for Pinealon mentions over the 2020–2026 window and found 3 papers. One is the Khavinson group's own mechanism review. One is a food-science paper on a related but different peptide. The third is a brief mention in a Khavinson-affiliated overview. There are zero Western randomized controlled trials.

Khavinson 2020 mechanism review. Published in Molecules, this paper lays out the MAPK/ERK pathway story, the antioxidant story, and the Alzheimer's-relevant signaling story (Khavinson et al., 2020). It's the most important single paper on Pinealon. It's also from the same lab making the original claims, which is what makes the single-source pattern so striking.

Jiang 2021 antioxidant paper. A Chinese food-science group studied a four-residue peptide called DREL (Asp-Arg-Glu-Leu) that contains EDR as its core. They showed antioxidant activity in vivo through the Nrf2/Keap1 stress-defense pathway (Jiang et al., 2021). DREL isn't Pinealon. It has an extra amino acid and a different arrangement. But it's the closest thing to independent, non-Khavinson evidence that EDR-containing short peptides have real antioxidant biology.

What's missing from the literature. No Western randomized trials of Pinealon for any indication. No independent test of the direct-histone-binding model. No human pharmacokinetic data showing how it's absorbed or how long it lasts. No long-term safety data.

What does it stack with?

In the Khavinson literature, Pinealon plus Epitalon represents a combination investigated within the same research program. Both are from the same Saint Petersburg lineage. No published Western trial has evaluated this combination or established any co-administration regimen.

Some Khavinson-affiliated reports have mentioned Pinealon alongside the Russian-approved cognitive peptides Selank or Semax. The proposed rationale is that those compounds act on classical neurotransmitter pathways, while Pinealon is proposed to act on gene expression. No published trial has tested any of these co-administration scenarios.

Reconstitution and storage

1. Inspect the vial. Lyophilized Pinealon should present as a fine white powder or thin disc at the bottom. Discoloration is a sign of degradation.
2. Select a diluent. Bacteriostatic water is appropriate for multi-day storage. Sterile water is suitable for single-use applications. See our peptide reconstitution guide for additional detail.
3. Add diluent slowly down the vial wall. Swirl gently. Do not shake.
4. Storage: lyophilized powder at –20°C is stable for 24+ months. Reconstituted solution should be stored at 2–8°C and used within 14–28 days. Avoid freeze-thaw cycles.

What about side effects?

There is no published human safety surveillance on Pinealon specifically. The Khavinson clinical-practice literature references mild tolerability observations, but no systematic safety data exist for this compound.

• Observations in Khavinson clinical tradition: mild injection-site reactions have been noted. Transient headache was mentioned in some early-course observations.
• Less frequently noted: changes in sleep patterns and mild GI discomfort have appeared in anecdotal reports.
• Uncharacterized theoretical concerns: chronic exposure to a peptide proposed to bind DNA-packaging proteins raises unresolved autoimmune and genotoxicity questions. Drug interactions have not been studied.

Khavinson-school peptides

Research-grade ≥99% pure Lyophilized

Three-residue Pinealon (EDR) isn’t in our catalog today; our nearest stocked Khavinson-school peptide is Epitalon (AEDG), with the same Saint Petersburg lineage and slightly broader Western mechanism work. Each lot ships with a third-party CoA documenting identity and purity.

Browse the catalog

Is it legal? Is it FDA-approved?

Pinealon is not FDA-approved for any indication. It is not approved by the EMA either. It has Russian preclinical research history through the Khavinson program, but it doesn't appear to hold a formal therapeutic registration even in Russia.

In the United States, this means three things:

• Sale as a research compound is legal when the product is labeled for laboratory use only.
• Sale as a therapeutic is not legal. Marketing Pinealon for "cognitive enhancement" or "neuroprotection" in humans would draw FDA enforcement action.
• There is no FDA-recognized indication, so Pinealon doesn't participate in any therapeutic standard of care.

The DEA does not schedule Pinealon. It is not a controlled substance.

What about sports and WADA?

Pinealon is not explicitly listed on the WADA Prohibited List (WADA, 2026). But that doesn't make it safe to use as a tested athlete.

WADA's S0 category is a catch-all for any substance that has not received therapeutic approval but is being used for a performance purpose. As a non-approved peptide, Pinealon could fall under that umbrella for competing athletes.

The detection-window question is also unanswered. No published method specific to detecting EDR in urine or blood appears in the WADA-accredited literature. Any non-approved peptide should be treated as a compliance risk regardless of explicit list status.

Frequently asked questions

What is Pinealon, exactly?

A synthetic three-amino-acid peptide (Glu-Asp-Arg, abbreviated EDR), developed by the Saint Petersburg Institute of Bioregulation and Gerontology under Vladimir Khavinson. It's part of the same short-peptide program that produced Epitalon, and it's marketed for cognitive support. Research-stage. Not FDA- or EMA-approved.

Is Pinealon FDA-approved?

No. The FDA, EMA, and other Western regulators haven't approved it. It has Russian preclinical history through the Khavinson program. No jurisdiction approves it as a therapeutic. In the U.S. it's sold legally only as a research reference compound.

How does Pinealon work?

The Khavinson group proposes it binds DNA-packaging proteins (histones) or RNA directly and switches gene expression. Downstream, that supposedly affects MAPK/ERK signaling, antioxidant enzymes (SOD2, GPX1), pro-death signals (caspase-3, p53), and metabolic transcription factors (PPARA, PPARG). The model is the same one the group proposes for Epitalon. No outside lab has independently confirmed the histone-binding step.

How is Pinealon different from Epithalon?

Both are short peptides from the same Khavinson lab. Epitalon is 4 residues (AEDG) and is positioned as a longevity peptide with proposed telomerase activation. Pinealon is 3 residues (EDR) and is positioned for cognitive function. Epitalon has a slightly broader Western evidence base, including a 2025 telomerase replication from Brunel University. Pinealon has only 3 PubMed papers in 2020–2026.

Is the Russian research credible?

The Khavinson group has been publishing on short peptides since the 1970s, and the cell-biology work is methodically reported. But it isn't the same as Western RCT-grade evidence. Independent replication is essentially absent. Older Russian-language clinical reports aren't PubMed-indexed and can't be quality-reviewed by Western readers. The biology is plausible, not fictional. The breadth of supporting evidence is much narrower than consumer marketing suggests.

What human evidence exists?

None of Western RCT grade. The Khavinson 2020 review describes behavior-test improvements in rodents and "memory improvement in elderly patients" from older Russian clinical practice. That older clinical material isn't PubMed-indexed and isn't accessible for independent quality review.

How much does Pinealon cost?

Research-grade reference compound pricing in 2026 has been reported at $35–$80 per 10 mg vial across various suppliers. Given the thin Western evidence base, identity transparency — a mass-spectrometry CoA from an accredited laboratory — is an important consideration when evaluating any source.